{"id":5156,"date":"2025-05-01T20:00:06","date_gmt":"2025-05-01T20:00:06","guid":{"rendered":"https:\/\/medicalaffairs.travere.com\/?post_type=poster&#038;p=5156"},"modified":"2025-10-15T06:34:23","modified_gmt":"2025-10-15T06:34:23","slug":"protect-proteinuria-remission-egfr","status":"publish","type":"poster","link":"https:\/\/clleancode.top\/travere-redesign\/congress-materials\/protect-proteinuria-remission-egfr\/","title":{"rendered":"Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT"},"content":{"rendered":"<section class=\"o-hero-section o-hero--banner o-hero--blue o-hero--cropped\">\n        <div class=\"container\">\n        <div class=\"m-hero-inner m-hero-inner--post\">\n            <div class=\"m-breadcrumb\">\n                <nav class=\"breadcrumbs\" aria-label=\"breadcrumb\"><span><span><a href=\"https:\/\/clleancode.top\/travere-redesign\/\">Home<\/a><\/span><\/span><\/nav>            <\/div>\n            <h1 class=\"a-heading a-heading--h1 h-white\">Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT<\/h1>                    <\/div>\n    <\/div>\n<\/section>\n\n\n\n\r\n\t<section style=\"padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;margin-top:calc(-180px * var(--scale));\" class=\"section-container wp-elements-b1bd6a8bf7712bedf6bd438229aebc81 wp-block-grizzly-section-container has-text-color has-white-color\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div class=\"info-block info-block-publication search__container-publication search__container\">\n\t<div class=\"info-block-top\">\n\t\t<div>\n\t\t\t\t\t\t\t<div class=\"info-block-type\"><i class=\"icon2-journal\" aria-hidden=\"true\"><\/i> Poster<\/div>\n\t\t\t\n\t\t\t\t\t\t\t<div class=\"info-block-type\">\n\t\t\t\t\t<i class=\"icon2-calendar\" aria-hidden=\"true\"><\/i> Published on October 25, 2024\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t<p>Topics:<\/p>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">IgAN<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t<div class=\"info-block-bottom\">\n\t\t\t\t\t\t<div class=\"info-block-box\">\n\t\t\t\t\tContributors<br \/><span>Heerspink JLH, <br \/>\r\nTesar V, \u2028<br \/>\r\nKomers R et al.<\/span><br \/><br \/><br \/>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<div class=\"info-block-box\">\n\t\t\t\t\tPresented at:<br \/><span>ASN 2024<br \/>\r\nWCN 2025<br \/>\r\nANNA 2025<\/span><br \/><br \/><br \/>\n\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/ASN2024_Poster_PROTECT_Low-Proteinuria.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"btn btn-outline\">View poster<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\n\t\t<div class=\"info-block-share\">\n\t\t\tShare: \n\t\t\t<span>\n\t\t\t\t\t<a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fprotect-proteinuria-remission-egfr%2F&#038;text=Implications+of+Proteinuria+Remission+on+Estimated+Glomerular+Filtration+Rate+Trajectory+in+Patients+With+IgA+Nephropathy+in+PROTECT\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-x\" aria-label=\"Share on Twitter\"><\/a> \n\t<a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fprotect-proteinuria-remission-egfr%2F&#038;title=Implications+of+Proteinuria+Remission+on+Estimated+Glomerular+Filtration+Rate+Trajectory+in+Patients+With+IgA+Nephropathy+in+PROTECT\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-linkedin-2\" aria-label=\"Share on LinkedIn\"><\/a> \n\t<a href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fprotect-proteinuria-remission-egfr%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon-facebook\" aria-label=\"Share on Facebook\"><\/a> \n\t<a href=\"mailto:?subject=Implications%20of%20Proteinuria%20Remission%20on%20Estimated%20Glomerular%20Filtration%20Rate%20Trajectory%20in%20Patients%20With%20IgA%20Nephropathy%20in%20PROTECT&#038;body=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fprotect-proteinuria-remission-egfr%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-email-2\" aria-label=\"Share via Email\"><\/a>\n\t\t\t<\/span>\n\t\t<\/div>\n\t<\/div>\n<\/div><\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t\n\n\r\n\t<section style=\"padding-top:calc(30px * var(--scale));padding-right:0px;padding-bottom:0px;padding-left:0px;\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<h2 class=\"wp-block-heading has-text-align-center has-heading-4-font-size has-teal-color has-text-color has-link-color wp-elements-7c03867aaa7fc5649621991eef6259ee\" id=\"h-about-the-research\" style=\"margin-top:calc(60px * var(--scale));margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\">About the research<\/span><\/h2>\n\n\n\n<div class=\"pdf-block\">\n\t\t\t\t<iframe src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/ASN2024_Poster_PROTECT_Low-Proteinuria.pdf\" frameborder=\"0\"><\/iframe>\n\t\t<div class=\"pdf-block--buttons\">\n\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/ASN2024_Poster_PROTECT_Low-Proteinuria.pdf\" class=\"btn\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\"View\">View<\/a>\n\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/ASN2024_Poster_PROTECT_Low-Proteinuria.pdf\" class=\"btn btn-outline\" download aria-label=\"Download\">Download<\/a>\n\t<\/div>\n<\/div>\n\n\n<h3 class=\"wp-block-heading has-text-align-center has-heading-4-font-size has-teal-color has-text-color has-link-color wp-elements-66479faaeb38e9c5c0ee0d5b7d4e94d7\" id=\"h-summary\" style=\"margin-top:calc(60px * var(--scale));margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\">Summary<\/span><\/h3>\n\n\n\t<div class=\"feature-block feature-block--left\">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"has-heading-5-font-size\">Background<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><ul>\n<li>Sparsentan, a non-immunosuppressive, <a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/protective-mechanism-sparsentan-chronic-kidney-disease-models\/\" target=\"_blank\" rel=\"noopener\">Dual Endothelin Angiotensin Receptor Antagonist (DEARA)<\/a>, is indicated to slow kidney function decline in adults with IgA nephropathy who are at risk of disease progression<sup>1-3<\/sup><\/li>\n<li>In the <a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/efficacy-and-safety-of-sparsentan-versus-irbesartan-in-patients-with-iga-nephropathy-protect-2-year-results-from-a-randomised-active-controlled-phase-3-trial-2\/\" target=\"_blank\" rel=\"noopener\">PROTECT trial, sparsentan reduced proteinuria and increased the proportion of patients achieving complete remission<\/a> versus the maximum labeled dose of irbesartan<sup>4<\/sup><\/li>\n<li>In IgA nephropathy, proteinuria is significantly associated with worse kidney outcomes and reduction has been shown to predict slower disease progression and lower risk of kidney failure<sup>5,6<\/sup><\/li>\n<\/ul>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-1.jpg\" >\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"320\" height=\"380\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-1.jpg\" class=\"attachment-full size-full\" alt=\"PROTECT study logo\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-1.jpg 320w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-1-253x300.webp 253w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-1-290x344.webp 290w\" sizes=\"auto, (max-width: 320px) 100vw, 320px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading has-heading-5-font-size has-ocean-blue-color has-text-color has-link-color wp-elements-2b8f88743582f7a51b969a7d7be06013\" id=\"h-aim\"><span class=\"fw-600\">Aim<\/span><\/h4>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>To determine the estimated glomerular filtration rate (eGFR) trajectories of patients who achieved complete remission (CR) of proteinuria (&lt;0.3 g\/d) or urinary protein excretion (UPE) &lt;0.5 g\/d at any time during the 110-week PROTECT trial<br>versus those who did not<sup>1<\/sup><br><br>This treatment agnostic analysis will determine whether these levels of proteinuria reduction were associated with<br>favorable outcomes<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-study-design.png\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2001\" height=\"594\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-study-design.png\" class=\"attachment-full size-full\" alt=\"PROTECT study design\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-study-design.png 2001w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-study-design-300x89.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-study-design-1024x304.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-study-design-768x228.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-study-design-1536x456.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-study-design-290x86.webp 290w\" sizes=\"auto, (max-width: 2001px) 100vw, 2001px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-blue-color has-text-color has-link-color wp-elements-57a28d9d19829f97381235df76d96755\"><strong>Figure. PROTECT study design<\/strong><\/p>\n\n\n\n<p><br>PROTECT is a large, international, randomized, double-blind, active-controlled Phase 3 trial to assess the efficacy and safety \u2028of sparsentan versus irbesartan<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<details class=\"wp-block-details\"><summary><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color is-layout-flow wp-block-details-is-layout-flow\">About the figure<\/mark><\/strong><\/summary>\n<p>Participants were randomly assigned to the treatment, sparsentan or active-controlled, maximum labeled dose irbesartan group<sup>1<\/sup><br><br>Study included a 110-week double-blind treatment period and 4 weeks of study drug withdrawal. Interim analysis occurred at 36 weeks. Two-year follow-up occurred at 110 weeks<sup>1<\/sup><\/p>\n<\/details>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading has-ocean-blue-color has-text-color has-link-color wp-elements-fc8b38e57abe42a75f3c7d9da94d60b5\" id=\"h-key-findings\"><span class=\"fw-600\">Key findings<\/span><\/h5>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\">Patients who achieved proteinuria remission had similar demographics compared to those who did not except baseline UPE was lower and baseline eGFR was higher in patients who achieved remission<sup>1<\/sup><br><br>Overall, 21.0% (85\/404) and 37.4% (151\/404) of patients achieved CR and UPE &lt;0.5 g\/d, respectively<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\">Achieving CR and UPE &lt;0.5 g\/d was more common among patients receiving sparsentan than maximum labeled<br>dose irbesartan<sup>1<\/sup><br><br>The majority of patients who achieved proteinuria remission had been randomized to the sparsentan group, and the majority who did not had been randomized to the maximum labeled dose irbesartan group<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-3.png\" >\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"3000\" height=\"1105\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-3.png\" class=\"attachment-full size-full\" alt=\"Donut charts on CR and UPE\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-3.png 3000w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-3-300x111.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-3-1024x377.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-3-768x283.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-3-1536x566.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-3-2048x754.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-3-290x107.webp 290w\" sizes=\"auto, (max-width: 3000px) 100vw, 3000px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-navy-color\">Figure. Patients achieving CR or UPE &lt;0.5 g\/d by treatment assignment at any time from baseline through Week 110<\/mark><\/strong><br><\/p>\n\n\n\n<p>Patients were three times more likely to achieve CR with sparsentan compared to maximum labeled dose irbesartan (73% [62\/85] verus 27% [23\/85])<sup>1<\/sup><br><br>UPE &lt;0.5g\/d was achieved in 68% (103\/151) of patients with sparsentan versus 32% (48\/151) with irbesartan<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\">eGFR preservation was more evident in patients who achieved CR or UPE &lt;0.5 g\/d versus those who did not<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/egfr-protect-graphs.png\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2001\" height=\"1640\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/egfr-protect-graphs.png\" class=\"attachment-full size-full\" alt=\"Line graphs of eGFR over time\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/egfr-protect-graphs.png 2001w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/egfr-protect-graphs-300x246.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/egfr-protect-graphs-1024x839.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/egfr-protect-graphs-768x629.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/egfr-protect-graphs-1536x1259.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/egfr-protect-graphs-290x238.webp 290w\" sizes=\"auto, (max-width: 2001px) 100vw, 2001px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-navy-color\">Figure. Absolute change from baseline in eGFR at each study visit in patients who achieved A) CR or B) UPE &lt;0.5 g\/day<\/mark><sup><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\">a<\/mark><\/sup><\/strong><br><br>At any time through Week 110, in patients who achieved CR or UPE &lt;0.5 g\/day, eGFR acutely dropped in the first few weeks but stabilized through Week 110<sup>1<\/sup><br><br>In patients who never achieved CR or UPE &lt;0.5 g\/d, eGFR showed a smaller acute drop after which it steadily declined through Week 110<sup>1<\/sup><br><br><sup>a<\/sup>Change from baseline in eGFR by visit using a mixed model for repeated measures (MMRM) with on-study values and baseline UPE adjustment.<sup>1<\/sup><br><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<details class=\"wp-block-details\"><summary><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color is-layout-flow wp-block-details-is-layout-flow\">About the figure<\/mark><\/strong><\/summary>\n<p>At 2 years (Week 110), patients achieving CR experienced a slower kidney function decline than those who did not (-4.0 versus -8.9, Difference: 4.9)<sup>1<\/sup><br><br>At 2 years (Week 110), patients achieving UPE &lt;0.5 g\/day experienced a slower kidney function decline than those who did not (-4.3 versus -10.0, Difference: 5.7)<sup>1<\/sup><\/p>\n<\/details>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\">The rate of eGFR decline, represented by the chronic and total eGFR slopes,* was slower in patients who achieved CR or UPE &lt;0.5 g\/d versus those who did not<sup>1<\/sup><br><br>Notably, in patients who achieved CR at any time through Week 110, the mean rate of kidney function decline\u2028(eGFR chronic slope) was below the therapeutic goal of &lt;1.0 mL\/min\/1.73 m<sup>2<\/sup> per year<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/total-chronic-slope-table.png\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2001\" height=\"530\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/total-chronic-slope-table.png\" class=\"attachment-full size-full\" alt=\"Total and chronic slope table\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/total-chronic-slope-table.png 2001w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/total-chronic-slope-table-300x79.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/total-chronic-slope-table-1024x271.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/total-chronic-slope-table-768x203.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/total-chronic-slope-table-1536x407.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/total-chronic-slope-table-290x77.webp 290w\" sizes=\"auto, (max-width: 2001px) 100vw, 2001px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-blue-color has-text-color has-link-color wp-elements-410079b73cd9baa0af8a0162b2b59082\"><strong>Table. Total and chronic eGFR slopes from any time through Week 110<sup>b,c<\/sup><\/strong><\/p>\n\n\n\n<p><br>Patients achieving CR experienced a 4.1 difference in chronic slope (95% CI: 2.98 to 5.23, <em>P<\/em>&lt;0.0001) versus those who did not<sup>1<\/sup><br><br>Patients achieving UPE &lt;0.5 g\/d experienced a 4.0 difference in chronic slope (95% CI: 3.04 to 4.91, <em>P<\/em>&lt;0.0001) versus those who did not<sup>1<\/sup><br>&nbsp;<br><sup>a<\/sup>Baseline (Day 1) eGFR is included as a response variable and covariate.<sup>1<\/sup> <sup>b<\/sup>Based on on-study data.<sup>1<\/sup> <sup>c<\/sup>eGFR slopes were assessed using linear mixed effects model and adjusted for baseline log transformed UPE.<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<details class=\"wp-block-details\"><summary><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color is-layout-flow wp-block-details-is-layout-flow\">About the figure<\/mark><\/strong><\/summary>\n<p>Patients achieving CR experienced a 3.5 difference in total slope (95% CI: 2.41 to 4.63, <em>P<\/em>&lt;0.0001) versus those who did not<sup>1<\/sup><br><br>Patients achieving UPE &lt;0.5 g\/d experienced a 3.5 difference in total slope (95% CI: 2.55 to 4.40, <em>P<\/em>&lt;0.0001) versus those who did not<sup>1<\/sup><\/p>\n<\/details>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\">Markedly fewer patients who achieved CR or UPE g\/d reached composite kidney failure (KF)<sup>\u2020<\/sup> endpoint<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/kaplan-meier-plot-graphs.png\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2001\" height=\"622\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/kaplan-meier-plot-graphs.png\" class=\"attachment-full size-full\" alt=\"Kaplan-Meier plot for time to reach composite KF endpoint\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/kaplan-meier-plot-graphs.png 2001w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/kaplan-meier-plot-graphs-300x93.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/kaplan-meier-plot-graphs-1024x318.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/kaplan-meier-plot-graphs-768x239.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/kaplan-meier-plot-graphs-1536x477.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/kaplan-meier-plot-graphs-290x90.webp 290w\" sizes=\"auto, (max-width: 2001px) 100vw, 2001px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\">Figure. Kaplan-Meier plot for time to reach the composite KF endpoint in patients who achieved A) CR or B) UPE &lt;0.5 g\/d at any time through Week 110<\/mark><\/strong><br><br>Of patients who achieved CR or UPE &lt;0.5 g\/d, 1 (1.2%) and 6 (4.0%) respectively reached the composite KF<sup>\u2020<\/sup> endpoint<sup>1<\/sup><br><br>Of those who did not achieve CR or UPE &lt;0.5 g\/d, 43 (13.5%) and 38 (15.0%) respectively did not achieve the composite KF<sup>\u2020<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\">Treatment-emergent adverse events (TEAE) occurred in 79 (93%) patients who achieved CR versus 285 (89%) who did not achieve CR<sup>1<\/sup><br><br>The most common TEAEs were:<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul class=\"wp-block-list\">\n<li>COVID-19<sup>\u2021<\/sup><\/li>\n\n\n\n<li>Headache<\/li>\n\n\n\n<li>Hyperkalemia<\/li>\n\n\n\n<li>Edema peripheral<\/li>\n\n\n\n<li>Dizziness<\/li>\n\n\n\n<li>Hypotension<\/li>\n\n\n\n<li>Hypertension<\/li>\n<\/ul>\n<\/div>\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>TEAEs of interest were comparable between groups: <\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul class=\"wp-block-list\">\n<li>Hypotension<\/li>\n\n\n\n<li>Fluid retension<\/li>\n\n\n\n<li>Anemia<\/li>\n\n\n\n<li>Hyperkalemia<\/li>\n<\/ul>\n<\/div>\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block feature-block--half\">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"has-heading-5-font-size\">Conclusions<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><ul>\n<li>In IgA nephropathy, achievement of low proteinuria is strongly predictive of better long-term kidney function<sup>1<\/sup><\/li>\n<li>eGFR preservation was more evident in those who achieved low proteinuria versus those who did not<sup>1<\/sup><\/li>\n<li>Substantially fewer patients who achieved CR or UPE <0.5 g\/d reached the composite kidney failure endpoint than patients who did not<sup>1<\/sup><\/li>\n<li>In line with the findings from the <a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/efficacy-and-safety-of-sparsentan-versus-irbesartan-in-patients-with-iga-nephropathy-protect-2-year-results-from-a-randomised-active-controlled-phase-3-trial-2\/\" target=\"_blank\" rel=\"noopener\">PROTECT study<\/a>, this analysis further supports the interplay between proteinuria and kidney function decline, and the benefit of sparsentan for long-term preservation of kidney function<sup>1<\/sup><\/li>\n<\/ul>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/two-kidneys_header.png\" >\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"818\" height=\"767\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/two-kidneys_header.png\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/two-kidneys_header.png 818w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/two-kidneys_header-300x281.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/two-kidneys_header-768x720.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/two-kidneys_header-290x272.webp 290w\" sizes=\"auto, (max-width: 818px) 100vw, 818px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"newsletter\">\n\t<div class=\"newsletter-icon\">\n\t\t<span class=\"icon2-newsletter\"><\/span>\n\t<\/div>\n\t<div class=\"newsletter-text\">\n\t\t<p><strong>Sign up<\/strong> to receive scientific updates<br \/>\nfor healthcare professionals<br \/>\nfrom Travere Therapeutics.<\/p>\n\t<\/div>\n\t<div class=\"newsletter-form\">\n\t\t<script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\nvar gform;gform||(document.addEventListener(\"gform_main_scripts_loaded\",function(){gform.scriptsLoaded=!0}),document.addEventListener(\"gform\/theme\/scripts_loaded\",function(){gform.themeScriptsLoaded=!0}),window.addEventListener(\"DOMContentLoaded\",function(){gform.domLoaded=!0}),gform={domLoaded:!1,scriptsLoaded:!1,themeScriptsLoaded:!1,isFormEditor:()=>\"function\"==typeof InitializeEditor,callIfLoaded:function(o){return!(!gform.domLoaded||!gform.scriptsLoaded||!gform.themeScriptsLoaded&&!gform.isFormEditor()||(gform.isFormEditor()&&console.warn(\"The use of gform.initializeOnLoaded() is deprecated in the form editor context and will be removed in Gravity Forms 3.1.\"),o(),0))},initializeOnLoaded:function(o){gform.callIfLoaded(o)||(document.addEventListener(\"gform_main_scripts_loaded\",()=>{gform.scriptsLoaded=!0,gform.callIfLoaded(o)}),document.addEventListener(\"gform\/theme\/scripts_loaded\",()=>{gform.themeScriptsLoaded=!0,gform.callIfLoaded(o)}),window.addEventListener(\"DOMContentLoaded\",()=>{gform.domLoaded=!0,gform.callIfLoaded(o)}))},hooks:{action:{},filter:{}},addAction:function(o,r,e,t){gform.addHook(\"action\",o,r,e,t)},addFilter:function(o,r,e,t){gform.addHook(\"filter\",o,r,e,t)},doAction:function(o){gform.doHook(\"action\",o,arguments)},applyFilters:function(o){return gform.doHook(\"filter\",o,arguments)},removeAction:function(o,r){gform.removeHook(\"action\",o,r)},removeFilter:function(o,r,e){gform.removeHook(\"filter\",o,r,e)},addHook:function(o,r,e,t,n){null==gform.hooks[o][r]&&(gform.hooks[o][r]=[]);var d=gform.hooks[o][r];null==n&&(n=r+\"_\"+d.length),gform.hooks[o][r].push({tag:n,callable:e,priority:t=null==t?10:t})},doHook:function(r,o,e){var t;if(e=Array.prototype.slice.call(e,1),null!=gform.hooks[r][o]&&((o=gform.hooks[r][o]).sort(function(o,r){return o.priority-r.priority}),o.forEach(function(o){\"function\"!=typeof(t=o.callable)&&(t=window[t]),\"action\"==r?t.apply(null,e):e[0]=t.apply(null,e)})),\"filter\"==r)return e[0]},removeHook:function(o,r,t,n){var e;null!=gform.hooks[o][r]&&(e=(e=gform.hooks[o][r]).filter(function(o,r,e){return!!(null!=n&&n!=o.tag||null!=t&&t!=o.priority)}),gform.hooks[o][r]=e)}});\n\/* ]]> *\/\n<\/script>\n\n                <div class='gf_browser_gecko gform_wrapper gform-theme gform-theme--foundation gform-theme--framework gform-theme--orbital' data-form-theme='orbital' data-form-index='0' id='gform_wrapper_1' ><style>#gform_wrapper_1[data-form-index=\"0\"].gform-theme,[data-parent-form=\"1_0\"]{--gf-color-primary: #204ce5;--gf-color-primary-rgb: 32, 76, 229;--gf-color-primary-contrast: #fff;--gf-color-primary-contrast-rgb: 255, 255, 255;--gf-color-primary-darker: #001AB3;--gf-color-primary-lighter: #527EFF;--gf-color-secondary: #fff;--gf-color-secondary-rgb: 255, 255, 255;--gf-color-secondary-contrast: #112337;--gf-color-secondary-contrast-rgb: 17, 35, 55;--gf-color-secondary-darker: #F5F5F5;--gf-color-secondary-lighter: #FFFFFF;--gf-color-out-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-out-ctrl-light-rgb: 17, 35, 55;--gf-color-out-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-out-ctrl-light-lighter: #F5F5F5;--gf-color-out-ctrl-dark: #585e6a;--gf-color-out-ctrl-dark-rgb: 88, 94, 106;--gf-color-out-ctrl-dark-darker: #112337;--gf-color-out-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-color-in-ctrl: #fff;--gf-color-in-ctrl-rgb: 255, 255, 255;--gf-color-in-ctrl-contrast: #112337;--gf-color-in-ctrl-contrast-rgb: 17, 35, 55;--gf-color-in-ctrl-darker: #F5F5F5;--gf-color-in-ctrl-lighter: #FFFFFF;--gf-color-in-ctrl-primary: #204ce5;--gf-color-in-ctrl-primary-rgb: 32, 76, 229;--gf-color-in-ctrl-primary-contrast: #fff;--gf-color-in-ctrl-primary-contrast-rgb: 255, 255, 255;--gf-color-in-ctrl-primary-darker: #001AB3;--gf-color-in-ctrl-primary-lighter: #527EFF;--gf-color-in-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-in-ctrl-light-rgb: 17, 35, 55;--gf-color-in-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-in-ctrl-light-lighter: #F5F5F5;--gf-color-in-ctrl-dark: #585e6a;--gf-color-in-ctrl-dark-rgb: 88, 94, 106;--gf-color-in-ctrl-dark-darker: #112337;--gf-color-in-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-radius: 3px;--gf-font-size-secondary: 14px;--gf-font-size-tertiary: 13px;--gf-icon-ctrl-number: url(\"data:image\/svg+xml,%3Csvg width='8' height='14' viewBox='0 0 8 14' fill='none' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M4 0C4.26522 5.96046e-08 4.51957 0.105357 4.70711 0.292893L7.70711 3.29289C8.09763 3.68342 8.09763 4.31658 7.70711 4.70711C7.31658 5.09763 6.68342 5.09763 6.29289 4.70711L4 2.41421L1.70711 4.70711C1.31658 5.09763 0.683417 5.09763 0.292893 4.70711C-0.0976311 4.31658 -0.097631 3.68342 0.292893 3.29289L3.29289 0.292893C3.48043 0.105357 3.73478 0 4 0ZM0.292893 9.29289C0.683417 8.90237 1.31658 8.90237 1.70711 9.29289L4 11.5858L6.29289 9.29289C6.68342 8.90237 7.31658 8.90237 7.70711 9.29289C8.09763 9.68342 8.09763 10.3166 7.70711 10.7071L4.70711 13.7071C4.31658 14.0976 3.68342 14.0976 3.29289 13.7071L0.292893 10.7071C-0.0976311 10.3166 -0.0976311 9.68342 0.292893 9.29289Z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-icon-ctrl-select: url(\"data:image\/svg+xml,%3Csvg width='10' height='6' viewBox='0 0 10 6' fill='none' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M0.292893 0.292893C0.683417 -0.097631 1.31658 -0.097631 1.70711 0.292893L5 3.58579L8.29289 0.292893C8.68342 -0.0976311 9.31658 -0.0976311 9.70711 0.292893C10.0976 0.683417 10.0976 1.31658 9.70711 1.70711L5.70711 5.70711C5.31658 6.09763 4.68342 6.09763 4.29289 5.70711L0.292893 1.70711C-0.0976311 1.31658 -0.0976311 0.683418 0.292893 0.292893Z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-icon-ctrl-search: url(\"data:image\/svg+xml,%3Csvg width='640' height='640' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath d='M256 128c-70.692 0-128 57.308-128 128 0 70.691 57.308 128 128 128 70.691 0 128-57.309 128-128 0-70.692-57.309-128-128-128zM64 256c0-106.039 85.961-192 192-192s192 85.961 192 192c0 41.466-13.146 79.863-35.498 111.248l154.125 154.125c12.496 12.496 12.496 32.758 0 45.254s-32.758 12.496-45.254 0L367.248 412.502C335.862 434.854 297.467 448 256 448c-106.039 0-192-85.962-192-192z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-label-space-y-secondary: var(--gf-label-space-y-md-secondary);--gf-ctrl-border-color: #686e77;--gf-ctrl-size: var(--gf-ctrl-size-md);--gf-ctrl-label-color-primary: #112337;--gf-ctrl-label-color-secondary: #112337;--gf-ctrl-choice-size: var(--gf-ctrl-choice-size-md);--gf-ctrl-checkbox-check-size: var(--gf-ctrl-checkbox-check-size-md);--gf-ctrl-radio-check-size: var(--gf-ctrl-radio-check-size-md);--gf-ctrl-btn-font-size: var(--gf-ctrl-btn-font-size-md);--gf-ctrl-btn-padding-x: var(--gf-ctrl-btn-padding-x-md);--gf-ctrl-btn-size: var(--gf-ctrl-btn-size-md);--gf-ctrl-btn-border-color-secondary: #686e77;--gf-ctrl-file-btn-bg-color-hover: #EBEBEB;--gf-field-img-choice-size: var(--gf-field-img-choice-size-md);--gf-field-img-choice-card-space: var(--gf-field-img-choice-card-space-md);--gf-field-img-choice-check-ind-size: var(--gf-field-img-choice-check-ind-size-md);--gf-field-img-choice-check-ind-icon-size: var(--gf-field-img-choice-check-ind-icon-size-md);--gf-field-pg-steps-number-color: rgba(17, 35, 55, 0.8);}<\/style><div id='gf_1' class='gform_anchor' tabindex='-1'><\/div>\n                        <div class='gform_heading'>\n\t\t\t\t\t\t\t<p class='gform_required_legend'>&quot;<span class=\"gfield_required gfield_required_asterisk\">*<\/span>&quot; indicates required fields<\/p>\n                        <\/div><form method='post' enctype='multipart\/form-data' target='gform_ajax_frame_1' id='gform_1'  action='\/travere-redesign\/wp-json\/wp\/v2\/poster\/5156#gf_1' data-formid='1' novalidate>\n                        <div class='gform-body gform_body'><div id='gform_fields_1' class='gform_fields top_label form_sublabel_above description_below validation_below'><div id=\"field_1_2\" class=\"gfield gfield--type-text gfield--input-type-text gfield--width-half gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_2'>First Name<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_text'><input name='input_2' id='input_1_2' type='text' value='' class='large'    placeholder='First Name' aria-required=\"true\" aria-invalid=\"false\"   \/><\/div><\/div><div id=\"field_1_3\" class=\"gfield gfield--type-text gfield--input-type-text gfield--width-half gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_3'>Last Name<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_text'><input name='input_3' id='input_1_3' type='text' value='' class='large'    placeholder='Last Name' aria-required=\"true\" aria-invalid=\"false\"   \/><\/div><\/div><div id=\"field_1_1\" class=\"gfield gfield--type-email gfield--input-type-email gfield--width-full gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_1'>Email<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_email'>\n                            <input name='input_1' id='input_1_1' type='email' value='' class='medium'   placeholder='Your Email' aria-required=\"true\" aria-invalid=\"false\"  \/>\n                        <\/div><\/div><div id=\"field_1_4\" class=\"gfield gfield--type-captcha gfield--input-type-captcha gfield--width-full field_sublabel_above gfield--no-description field_description_below field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label screen-reader-text' for='input_1_4'><\/label><div id='input_1_4' class='ginput_container ginput_recaptcha' data-sitekey='6LdC-_4qAAAAAFq7fXBVZpv8VBlO518KAQ92yXpY'  data-theme='light' data-tabindex='-1' data-size='invisible' data-badge='bottomright'><\/div><\/div><\/div><\/div>\n        <div class='gform-footer gform_footer top_label'> <input type='submit' id='gform_submit_button_1' class='gform_button button' onclick='gform.submission.handleButtonClick(this);' data-submission-type='submit' value='Subscribe Now'  \/> <input type='hidden' name='gform_ajax' value='form_id=1&amp;title=&amp;description=&amp;tabindex=0&amp;theme=orbital&amp;styles=[]&amp;hash=19a707562f078a6ce83770354aeb3dd2' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submission_method' data-js='gform_submission_method_1' value='iframe' \/>\n            <input type='hidden' class='gform_hidden' name='gform_theme' data-js='gform_theme_1' id='gform_theme_1' value='orbital' \/>\n            <input type='hidden' class='gform_hidden' name='gform_style_settings' data-js='gform_style_settings_1' id='gform_style_settings_1' value='[]' \/>\n            <input type='hidden' class='gform_hidden' name='is_submit_1' value='1' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submit' value='1' \/>\n            \n            <input type='hidden' class='gform_hidden' name='gform_unique_id' value='' \/>\n            <input type='hidden' class='gform_hidden' name='state_1' value='WyJbXSIsIjY5OGM1NmFiMTIxOTFmZGIyYmVmMjY3YTI3NzY4MjVkIl0=' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_target_page_number_1' id='gform_target_page_number_1' value='0' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_source_page_number_1' id='gform_source_page_number_1' value='1' \/>\n            <input type='hidden' name='gform_field_values' value='' \/>\n            \n        <\/div>\n                        <\/form>\n                        <\/div>\n\t\t                <iframe style='display:none;width:0px;height:0px;' src='about:blank' name='gform_ajax_frame_1' id='gform_ajax_frame_1' title='This iframe contains the logic required to handle Ajax powered Gravity Forms.'><\/iframe>\n\t\t                <script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n gform.initializeOnLoaded( function() {gformInitSpinner( 1, 'https:\/\/clleancode.top\/travere-redesign\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', false );jQuery('#gform_ajax_frame_1').on('load',function(){var contents = jQuery(this).contents().find('*').html();var is_postback = contents.indexOf('GF_AJAX_POSTBACK') >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_1');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_1').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){jQuery('#gform_wrapper_1').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_1').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_1').removeClass('gform_validation_error');}setTimeout( function() { \/* delay the scroll by 50 milliseconds to fix a bug in chrome *\/ jQuery(document).scrollTop(jQuery('#gform_wrapper_1').offset().top - mt); }, 50 );if(window['gformInitDatepicker']) {gformInitDatepicker();}if(window['gformInitPriceFields']) {gformInitPriceFields();}var current_page = jQuery('#gform_source_page_number_1').val();gformInitSpinner( 1, 'https:\/\/clleancode.top\/travere-redesign\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', false );jQuery(document).trigger('gform_page_loaded', [1, current_page]);window['gf_submitting_1'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}jQuery('#gform_wrapper_1').replaceWith(confirmation_content);jQuery(document).scrollTop(jQuery('#gf_1').offset().top - mt);jQuery(document).trigger('gform_confirmation_loaded', [1]);window['gf_submitting_1'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_1').text());}else{jQuery('#gform_1').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger(\"gform_pre_post_render\", [{ formId: \"1\", currentPage: \"current_page\", abort: function() { this.preventDefault(); } }]);        if (event && event.defaultPrevented) {                return;        }        const gformWrapperDiv = document.getElementById( \"gform_wrapper_1\" );        if ( gformWrapperDiv ) {            const visibilitySpan = document.createElement( \"span\" );            visibilitySpan.id = \"gform_visibility_test_1\";            gformWrapperDiv.insertAdjacentElement( \"afterend\", visibilitySpan );        }        const visibilityTestDiv = document.getElementById( \"gform_visibility_test_1\" );        let postRenderFired = false;        function triggerPostRender() {            if ( postRenderFired ) {                return;            }            postRenderFired = true;            gform.core.triggerPostRenderEvents( 1, current_page );            if ( visibilityTestDiv ) {                visibilityTestDiv.parentNode.removeChild( visibilityTestDiv );            }        }        function debounce( func, wait, immediate ) {            var timeout;            return function() {                var context = this, args = arguments;                var later = function() {                    timeout = null;                    if ( !immediate ) func.apply( context, args );                };                var callNow = immediate && !timeout;                clearTimeout( timeout );                timeout = setTimeout( later, wait );                if ( callNow ) func.apply( context, args );            };        }        const debouncedTriggerPostRender = debounce( function() {            triggerPostRender();        }, 200 );        if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) {            const observer = new MutationObserver( ( mutations ) => {                mutations.forEach( ( mutation ) => {                    if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) {                        debouncedTriggerPostRender();                        observer.disconnect();                    }                });            });            observer.observe( document.body, {                attributes: true,                childList: false,                subtree: true,                attributeFilter: [ 'style', 'class' ],            });        } else {            triggerPostRender();        }    } );} ); \n\/* ]]> *\/\n<\/script>\n\t\t<div class=\"agreement\">\n\t\t\t<div id=\"agreement-box-newsletter\">\n\t\t\t\t<input type=\"checkbox\" id=\"agreement-check-newsletter\" \/>\n\t\t\t\t<label for=\"agreement-check-newsletter\"><\/label>\n\t\t\t\t<div id=\"agreement-box-tick-newsletter\">\n\t\t\t\t\t<span class=\"icon2-tick\"><\/span>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t<div>\n\t\t\t\t<p>I understand that by checking this box and clicking &#8220;Subscribe now&#8221; I am submitting my contact information and I consent to receive company communications from Travere Therapeutics.<\/p>\n\t\t\t\t<p>All personal information will be processed by or on behalf of Travere to provide access to company information and engage in marketing activities. Travere will retain personal information only for as long as is required to complete the purposes for which it was collected and to fulfill its legal, regulatory, or reporting obligations. Travere understands personal information is private and will not sell this personal information or disseminate it to third parties who are not providing services to Travere. You may unsubscribe at any time. For more information, review the <a href=\"https:\/\/travere.com\/privacy\/\" target=\"_blank\" rel=\"noopener\">Travere  privacy policies<\/a>.<\/p>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div id=\"invalid-newsletter\" class=\"invalid\">\n\t\t\t<div id=\"invalid-box-newsletter\">\n\t\t\t\t<span class=\"icon2-info-fill\"><\/span>\n\t\t\t<\/div>\n\t\t\t<div>\n\t\t\t\t<p><strong>Invalid email address.<\/strong><br \/>\n\t\t\t\tMake sure email is in correct format: <a href=\"\">name@example.com<\/a><\/p>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center\" id=\"h-see-more-research-from-travere\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\"><span class=\"fw-600\">See more research from Travere<\/span><\/mark><\/h4>\n\n\n  <div class=\"carousel-posts poster-carousel swiper carousel-type-poster wp-block-grizzly-posts-carousel\">\n    <div class=\"swiper-wrapper\">\n      <div class=\"swiper-slide\">\t<article class=\"m-card m-card--no-image \" aria-label=\"Congress material card: Patient-Reported Outcomes in the PROTECT Clinical Trial Comparing Sparsentan With Irbesartan for Immunoglobulin A Nephropathy\u00a0\">\n\t\t<div class=\"m-card__top\">\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-poster\"><\/i> Congress material\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">IgAN<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-w-medium\">Patient-Reported Outcomes in the PROTECT Clinical Trial Comparing Sparsentan With Irbesartan for Immunoglobulin A Nephropathy\u00a0<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2024\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-btns\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/ASN2024_Poster_PROTECT-PRO.pdf\" target=\"_blank\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Learn more: Patient-Reported Outcomes in the PROTECT Clinical Trial Comparing Sparsentan With Irbesartan for Immunoglobulin A Nephropathy\u00a0\">Learn more<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/article>\n<\/div><div class=\"swiper-slide\">\t<article class=\"m-card m-card--no-image \" aria-label=\"Congress material card: Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)\">\n\t\t<div class=\"m-card__top\">\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-poster\"><\/i> Congress material\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">IgAN<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-w-medium\">Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2024\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-btns\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/congress-materials\/sparsentan-sglt2i-iga-nephropathy-protect-ole\/\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Read more: Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)\">\n\t\t\t\t\t\t\t\t<span>Read more<\/span>\n\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/article>\n<\/div><div class=\"swiper-slide\">\t<article class=\"m-card m-card--no-image \" aria-label=\"Congress material card: PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g\/g\">\n\t\t<div class=\"m-card__top\">\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-poster\"><\/i> Congress material\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">IgAN<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-w-medium\">PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g\/g<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2024\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-btns\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/congress-materials\/protect-subgroup-analysis-proteinuria\/\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Read more: PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g\/g\">\n\t\t\t\t\t\t\t\t<span>Read more<\/span>\n\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/article>\n<\/div>    <\/div>\n    <div class=\"swiper-pagination\"><\/div>\n          <\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading has-ocean-blue-color has-text-color has-link-color wp-elements-3f0df576a3983c740201e9825d046f6f\" id=\"h-footnotes\" style=\"margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\">Footnotes<\/span><\/h5>\n\n\n\n<p class=\"has-small-font-size\" style=\"margin-bottom:calc(30px * var(--scale))\">*eGFR chronic slope was measured from Week 6 to Week 110 following the initial acute effect of randomized treatment.<sup>4-7 <\/sup>eGFR total slope was measured over the full double-blind study period \u2028(i.e., Day 1 to Week 110).<sup>4<\/sup> <sup>\u2020<\/sup>The composite KF endpoint was defined as confirmed 40% eGFR decline, end-stage kidney disease (initiation of renal replacement therapy or sustained eGFR &lt;15 mL\/min per 1.73 m<sup>2<\/sup>), or mortality due to any cause.<sup>1<\/sup> <sup>\u2021<\/sup>This study overlapped with the COVID-19 pandemic.<br><br>ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval; COVID-19, coronavirus disease 2019; CR, complete remission; DEARA, Dual Endothelin Angiotensin Receptor Antagonist; eGFR, estimated glomerular filtration rate; IgA, immunoglobulin A; KF, kidney failure; MMRM, mixed model for repeated measures; SOC, standard of care; TEAE, treatment-emergent adverse event; UPE, urine protein excretion.<\/p>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ol class=\"wp-block-list\">\n<li class=\"has-small-font-size\">Heerspink JLH et al. Poster presented at: American Society of Nephrology, 2024; October 23-27, 2024; San Diego, USA. FR-PO872.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Filspari\u00ae (sparsentan). Prescribing Information. San Diego, CA: Travere Therapeutics, Inc. 9\/2024.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Filspari\u00ae (sparsentan). Summary of Product Characteristics. Paris, France: Vifor France. 7\/2024.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Rovin BH et al. <em>Lancet<\/em>. 2023;402(10417):2077-2090.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Thompson A et al. <em>Clin J Am Soc Nephrol<\/em>. 2019:14;469-481.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Inker LA et al. <em>Am J Kidney Dis<\/em>. 2021:78;340-349.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Rovin BH et al. <em>Lancet<\/em>. 2023;402(10417):2077-2090. Supplemental Materials.<\/li>\n<\/ol>\n<\/div>\n\n\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-right\" style=\"margin-top:calc(30px * var(--scale));margin-bottom:calc(300px * var(--scale))\">MA-SP-24-0138 |  October 2024<\/p>\n<\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t","protected":false},"featured_media":0,"template":"","meta":{"inline_featured_image":false,"header_bg_color":"transparent","header_fixed":true,"post_description":"","post_download_link":"","pdf_file_link":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/05\/ASN2024_Poster_PROTECT_Low-Proteinuria.pdf"},"product":[78],"therapeutic_area":[97],"disease_area":[174],"study_registry":[175],"study_type":[176],"resource_type":[199,180],"class_list":["post-5156","poster","type-poster","status-publish","hentry","product-spa","therapeutic_area-neph","disease_area-igan","study_registry-protect","study_type-clinical","resource_type-poster","resource_type-summary"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.9 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>PROTECT Post Hoc Analysis: Proteinuria Remission | Travere Medical Affairs<\/title>\n<meta name=\"description\" content=\"Learn more about the PROTECT post hoc analysis, which evaluated kidney function based on proteinuria remission achievement. Read now.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT\" \/>\n<meta property=\"og:description\" content=\"Learn more about the PROTECT post hoc analysis, which evaluated kidney function based on proteinuria remission achievement. Read now.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-proteinuria-remission-egfr\/\" \/>\n<meta property=\"og:site_name\" content=\"Travere Medical Affairs\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TravereRare\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T06:34:23+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@TravereRare\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protect-proteinuria-remission-egfr\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protect-proteinuria-remission-egfr\\\/\",\"name\":\"PROTECT Post Hoc Analysis: Proteinuria Remission | Travere Medical Affairs\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\"},\"datePublished\":\"2025-05-01T20:00:06+00:00\",\"dateModified\":\"2025-10-15T06:34:23+00:00\",\"description\":\"Learn more about the PROTECT post hoc analysis, which evaluated kidney function based on proteinuria remission achievement. Read now.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protect-proteinuria-remission-egfr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protect-proteinuria-remission-egfr\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protect-proteinuria-remission-egfr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PROTECT Proteinuria Remission Analysis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"name\":\"Travere Medical Affairs\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\",\"name\":\"Travere Therapeutics\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"width\":420,\"height\":152,\"caption\":\"Travere Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/TravereRare\\\/\",\"https:\\\/\\\/x.com\\\/TravereRare\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PROTECT Post Hoc Analysis: Proteinuria Remission | Travere Medical Affairs","description":"Learn more about the PROTECT post hoc analysis, which evaluated kidney function based on proteinuria remission achievement. Read now.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT","og_description":"Learn more about the PROTECT post hoc analysis, which evaluated kidney function based on proteinuria remission achievement. Read now.","og_url":"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-proteinuria-remission-egfr\/","og_site_name":"Travere Medical Affairs","article_publisher":"https:\/\/www.facebook.com\/TravereRare\/","article_modified_time":"2025-10-15T06:34:23+00:00","twitter_card":"summary_large_image","twitter_site":"@TravereRare","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-proteinuria-remission-egfr\/","url":"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-proteinuria-remission-egfr\/","name":"PROTECT Post Hoc Analysis: Proteinuria Remission | Travere Medical Affairs","isPartOf":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#website"},"datePublished":"2025-05-01T20:00:06+00:00","dateModified":"2025-10-15T06:34:23+00:00","description":"Learn more about the PROTECT post hoc analysis, which evaluated kidney function based on proteinuria remission achievement. Read now.","breadcrumb":{"@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-proteinuria-remission-egfr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clleancode.top\/travere-redesign\/posters\/protect-proteinuria-remission-egfr\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-proteinuria-remission-egfr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clleancode.top\/travere-redesign\/"},{"@type":"ListItem","position":2,"name":"PROTECT Proteinuria Remission Analysis"}]},{"@type":"WebSite","@id":"https:\/\/clleancode.top\/travere-redesign\/#website","url":"https:\/\/clleancode.top\/travere-redesign\/","name":"Travere Medical Affairs","description":"","publisher":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clleancode.top\/travere-redesign\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/clleancode.top\/travere-redesign\/#organization","name":"Travere Therapeutics","url":"https:\/\/clleancode.top\/travere-redesign\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","width":420,"height":152,"caption":"Travere Therapeutics"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/TravereRare\/","https:\/\/x.com\/TravereRare"]}]}},"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-24 12:23:10","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"product","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/poster\/5156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/poster"}],"about":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/types\/poster"}],"wp:attachment":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media?parent=5156"}],"wp:term":[{"taxonomy":"product","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/product?post=5156"},{"taxonomy":"therapeutic_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/therapeutic_area?post=5156"},{"taxonomy":"disease_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/disease_area?post=5156"},{"taxonomy":"study_registry","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_registry?post=5156"},{"taxonomy":"study_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_type?post=5156"},{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/resource_type?post=5156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}